{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:58:22Z","timestamp":1790132302827,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,1,17]],"date-time":"2009-01-17T00:00:00Z","timestamp":1232150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11102-008-0162-y","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T09:53:01Z","timestamp":1232099581000},"page":"351-357","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma"],"prefix":"10.1007","volume":"14","author":[{"given":"Alessandra","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tilaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tofani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Barini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libero","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Maira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,17]]},"reference":[{"key":"162_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao AM, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265\u2013273. doi: 10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"162_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189\u2013225","journal-title":"Physiol Rev"},{"key":"162_CR3","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jc.86.11.5256","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano AG, Lombardi G, Colao AM (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 86:5256\u20135261. doi: 10.1210\/jc.86.11.5256","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","volume":"8","author":"ME Molitch","year":"2005","unstructured":"Molitch ME (2005) Pharmacological resistance in prolactinoma patients. Pituitary 8:43\u201352. doi: 10.1007\/s11102-005-5085-2","journal-title":"Pituitary"},{"key":"162_CR5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao AM (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485\u2013534. doi: 10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"162_CR6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500\u2013509","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","volume":"8","author":"DK Hamilton","year":"2005","unstructured":"Hamilton DK, Vance ML, Boulos PT, Laws ER (2005) Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8:53\u201360. doi: 10.1007\/s11102-005-5086-1","journal-title":"Pituitary"},{"key":"162_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horwath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99\u2013106. doi: 10.1097\/00006123-199601000-00024","journal-title":"Neurosurgery"},{"key":"162_CR9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","volume":"147","author":"E Delgrange","year":"2005","unstructured":"Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147:751\u2013758. doi: 10.1007\/s00701-005-0498-2","journal-title":"Acta Neurochir (Wien)"},{"key":"162_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1227\/01.NEU.0000223437.51435.6E","volume":"59","author":"BW Scheithauer","year":"2006","unstructured":"Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341\u2013353. doi: 10.1227\/01.NEU.0000223437.51435.6E","journal-title":"Neurosurgery"},{"key":"162_CR11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jc.79.3.724","volume":"79","author":"Y Greenman","year":"1994","unstructured":"Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724\u2013729. doi: 10.1210\/jc.79.3.724","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2826.1996.tb00695.x","volume":"8","author":"H Murabe","year":"1996","unstructured":"Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K (1996) Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J Neuroendocrinol 8:605\u2013610. doi: 10.1111\/j.1365-2826.1996.tb00695.x","journal-title":"J Neuroendocrinol"},{"key":"162_CR13","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1210\/jc.84.9.3268","volume":"84","author":"P Jaquet","year":"1999","unstructured":"Jaquet P, Quafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268\u20133276. doi: 10.1210\/jc.84.9.3268","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jcp.2005.026914","volume":"59","author":"E Thodou","year":"2006","unstructured":"Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M (2006) Mapping of somatostatin receptor types in GH or\/and PRL producing pituitary adenomas. J Clin Pathol 59:274\u2013279. doi: 10.1136\/jcp.2005.026914","journal-title":"J Clin Pathol"},{"key":"162_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","volume":"12","author":"SWJ Lamberts","year":"1991","unstructured":"Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endocr Rev 12:450\u2013482","journal-title":"Endocr Rev"},{"key":"162_CR16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s002590050269","volume":"25","author":"M Schmidt","year":"1998","unstructured":"Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrant G, Klung N, Schicha H (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675\u2013686. doi: 10.1007\/s002590050269","journal-title":"Eur J Nucl Med"},{"key":"162_CR17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF03343538","volume":"22","author":"A Colao","year":"1999","unstructured":"Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G (1999) The pituitary uptake of 111In-DPTA-DPhe1-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 22:176\u2013183","journal-title":"J Endocrinol Invest"},{"key":"162_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1259\/bjr\/51245688","volume":"78","author":"MJ Acosta-Gomez","year":"2005","unstructured":"Acosta-Gomez MJ, Muros MA, Llamas-elvira JM, Ramirez A, Ortega S, Sabatel G, Ramos C, a Aguilar A (2005) The role of somatostatin receptor scintigraphy in patients with pituitari adenoma or post-surgical recurrent tumours. Br J Radiol 78:110\u2013115. doi: 10.1259\/bjr\/51245688","journal-title":"Br J Radiol"},{"key":"162_CR19","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","volume":"100","author":"I Shimon","year":"1997","unstructured":"Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S (1997) Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 100:2386\u20132392. doi: 10.1172\/JCI119779","journal-title":"J Clin Invest"},{"key":"162_CR20","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1210\/jc.82.9.3011","volume":"82","author":"LJ Hofland","year":"1997","unstructured":"Hofland LJ, de Herder WW, Visser-Visselaar HA, van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJM, van Koetsveld PM, Lamberts WJ (1997) Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release on a small subgroup of pituitary- and islet cell tumours. J Clin Endocrinol Metab 82:3011\u20133018. doi: 10.1210\/jc.82.9.3011","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem-60-3-599","volume":"60","author":"M Ishibashi","year":"1985","unstructured":"Ishibashi M, Yamaji T (1985) Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture. J Clin Endocrinol Metab 60:599\u2013606","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooji D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts WJ (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577\u20131585. doi: 10.1210\/jc.2003-031344","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR23","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","volume":"89","author":"RD Murray","year":"2004","unstructured":"Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Brun C, Melmed S (2004) The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 89:3027\u20133032. doi: 10.1210\/jc.2003-031319","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1986.tb01683.x","volume":"25","author":"SW Lamberts","year":"1986","unstructured":"Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201\u2013995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 25:201\u2013212. doi: 10.1111\/j.1365-2265.1986.tb01683.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"162_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1011796","volume":"19","author":"MD Bronstein","year":"1987","unstructured":"Bronstein MD, Knoepfelmacher M, Liberman B, Marino R Jr, Germek OA, Shally AV (1987) Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm Metab Res 19:271\u2013274. doi: 10.1055\/s-2007-1011796","journal-title":"Horm Metab Res"},{"key":"162_CR26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2005-1837","volume":"91","author":"S Grottoli","year":"2006","unstructured":"Grottoli S, Gasco V, Broglio F, Baldelli R, Ragazzoni F, Gallenca F, Mainolfi A, Prodam F, Muccioli G, Ghigo E (2006) Cortistatin-17 and Somatostatin-14 display the same effects on growth hormone, prolactin and insulin secretion in patients with acromegaly or prolactinoma. J Clin Endocrinol Metab 91:1595\u20131599. doi: 10.1210\/jc.2005-1837","journal-title":"J Clin Endocrinol Metab"},{"key":"162_CR27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 288:154\u2013157. doi: 10.1126\/science.288.5463.154","journal-title":"Science"},{"key":"162_CR28","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1210\/en.2007-0378","volume":"148","author":"A Gruszka","year":"2007","unstructured":"Gruszka A, Ren SG, Dong J, Culler MD, Melmed S (2007) Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 148:6107\u20136114. doi: 10.1210\/en.2007-0378","journal-title":"Endocrinology"},{"key":"162_CR29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-07-0806","volume":"158","author":"A Fusco","year":"2008","unstructured":"Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A (2008) Somatostatinergic ligands in dopamine-sensitive and resistant prolactinomas. Eur J Endocrinol 158:595\u2013603. doi: 10.1530\/EJE-07-0806","journal-title":"Eur J Endocrinol"},{"key":"162_CR30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346. doi: 10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"key":"162_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 356:29\u201338. doi: 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"issue":"9","key":"162_CR32","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8\u00a0years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93(9):3348\u20133356. doi: 10.1210\/jc.2007-2658","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"162_CR33","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"A Wakil","year":"2008","unstructured":"Wakil A, Rigby A, Clark A, Atkin S (2008) Low dose cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159(4):R11\u2013R14 Epub 2008 Jul 14","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"162_CR34","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D\u2019Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93(10):3777\u20133784. doi: 10.1210\/jc.2007-1403","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-008-0162-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-008-0162-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-008-0162-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T06:08:08Z","timestamp":1559369288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-008-0162-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,17]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s11102-008-0162-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,17]]}}}